SYMMETREL Drug Patent Profile

Which patents cover Symmetrel, and what generic alternatives are available?

Symmetrel is a drug marketed by Endo Pharms and is included in three NDAs.

The generic ingredient in SYMMETREL is amantadine hydrochloride. There is one drug master file entry for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the amantadine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Symmetrel

A generic version of SYMMETREL was approved as amantadine hydrochloride by UPSHER SMITH LABS on August 5^th, 1986.

Summary for SYMMETREL

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
Patent Applications:	3,255
DailyMed Link:	SYMMETREL at DailyMed

Recent Clinical Trials for SYMMETREL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Columbia University	Phase 4
American Heart Association	Phase 2
University of Pittsburgh	Phase 2

See all SYMMETREL clinical trials

US Patents and Regulatory Information for SYMMETREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Pharms	SYMMETREL	amantadine hydrochloride	CAPSULE;ORAL	016020-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Endo Pharms	SYMMETREL	amantadine hydrochloride	SYRUP;ORAL	016023-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Endo Pharms	SYMMETREL	amantadine hydrochloride	TABLET;ORAL	018101-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Symmetrel Market Dynamics and Financial Trajectory: Amantadine Revenue, Generic Competition, Patents, and Commercial Outlook

Last updated: August 14, 2026

Symmetrel is the former brand name for amantadine hydrochloride, an inexpensive small-molecule drug approved in the United States for Parkinson's disease and drug-induced extrapyramidal reactions. Its influenza indication has lost commercial relevance because circulating influenza A viruses are generally resistant to adamantanes. The brand has no meaningful current U.S. growth profile; commercial activity is concentrated in low-cost generic amantadine, while extended-release products such as Gocovri and Osmolex ER have captured higher-value Parkinson's-related use cases.[1-4]

What is Symmetrel and how is it used?

Symmetrel contains amantadine hydrochloride, an adamantane derivative with dopaminergic and antiviral pharmacology. The original U.S. label covered:

• Parkinson's disease and Parkinsonism.
• Drug-induced extrapyramidal reactions.
• Prophylaxis and treatment of uncomplicated influenza A virus infection.[1]

Amantadine is available in oral capsules, tablets, and oral solution products. The most commercially relevant current uses are Parkinsonian symptoms and drug-induced movement disorders. Its historic influenza market has contracted sharply.

How does amantadine work?

Amantadine has several pharmacologic effects. It increases dopaminergic activity in the central nervous system and has activity at the N-methyl-D-aspartate receptor. Its antiviral mechanism involves interference with the influenza A M2 ion channel, but widespread resistance has eliminated routine use against seasonal influenza A in the United States.[3]

The drug's pharmacology creates a split market:

Market segment	Commercial status	Main products
Generic immediate-release amantadine	Mature, low-priced	Generic capsules, tablets, and solution
Former Symmetrel brand	Limited or discontinued commercial relevance	Symmetrel
Extended-release amantadine for dyskinesia	Higher-value branded niche	Gocovri
Extended-release amantadine for Parkinson's disease	Branded specialty niche	Osmolex ER
Influenza A treatment and prophylaxis	Largely obsolete in the U.S.	Amantadine generics are not recommended for routine use

What is the FDA regulatory status of Symmetrel?

Symmetrel was approved decades ago, and its core approvals are no longer commercially differentiated by regulatory exclusivity. The product is not a new chemical entity, and any original FDA exclusivity period expired long ago.

The FDA-approved amantadine market now consists mainly of generic products and separately approved extended-release formulations. Gocovri, developed by Adamas Pharmaceuticals and later acquired by Supernus Pharmaceuticals, was approved in 2017 for levodopa-induced dyskinesia in patients with Parkinson's disease.[4] Osmolex ER was approved in 2018 for Parkinson's disease and drug-induced extrapyramidal reactions.[5]

The regulatory structure is therefore divided between:

1. Legacy immediate-release amantadine products.
2. Generic equivalents referencing older amantadine products.
3. Newer extended-release products supported by formulation, dosing, and clinical-use patents.

What is the Orange Book status of Symmetrel?

Symmetrel's original product approvals do not create a meaningful current Orange Book barrier to generic amantadine. The relevant commercial question is whether a particular generic manufacturer faces patents listed against a newer extended-release product, not whether the legacy immediate-release Symmetrel brand retains enforceable exclusivity.

Gocovri and Osmolex ER have had product-specific patent listings and associated litigation risk. Those patents do not generally block generic immediate-release amantadine because the products differ in dosage form, release profile, labeling, and approved use.[4-6]

When did Symmetrel lose market exclusivity?

Symmetrel lost practical market exclusivity decades ago. Amantadine is a long-established generic active ingredient, and no current composition-of-matter protection is expected to constrain ordinary immediate-release competition.

Symmetrel patent expiration timeline

Protection category	Status	Commercial effect
Original amantadine composition protection	Expired decades ago	No barrier to generic entry
Original Symmetrel formulation protection	Expired or commercially irrelevant	Immediate-release competition is established
Historic influenza method-of-use protection	Expired or obsolete	No material revenue protection
Extended-release formulation patents	Product-specific and later filed	Can protect Gocovri or Osmolex ER
Parkinson's disease and dyskinesia method-of-use patents	Product-specific	May delay branded extended-release substitution

A definitive current patent conclusion requires review of each product's FDA Orange Book listings, patent family, terminal disclaimers, and litigation history. For the legacy Symmetrel immediate-release product, the commercial conclusion is clear: patent expiry is not the main market variable. Price, supply, prescribing volume, and payer coverage determine the remaining opportunity.

How large is the Symmetrel and amantadine market?

There is no reliable standalone public revenue series for Symmetrel as a brand. The brand has been displaced by generic amantadine, and U.S. prescription data typically report products by active ingredient, manufacturer, and dosage form rather than by the historical Symmetrel franchise.

The market has three distinct economic layers:

Low-value generic amantadine

Immediate-release amantadine is a mature generic with multiple suppliers. Generic pricing is typically constrained by:

• Multiple abbreviated new drug application holders.
• Low manufacturing complexity.
• Therapeutic substitution.
• Retail and mail-order pharmacy purchasing power.
• Limited clinical differentiation.
• Small molecule production using established chemistry.

Unit prices can rise during temporary shortages, but sustained pricing power is limited. The product is more exposed to supply-chain economics than to innovation-based pricing.

Specialty extended-release amantadine

Extended-release products have a different revenue model. Gocovri is positioned for levodopa-induced dyskinesia, a complication affecting a subset of Parkinson's patients. Its value proposition comes from once-daily dosing, pharmacokinetic design, and an approved indication specifically tied to dyskinesia.[4]

Osmolex ER targets Parkinson's disease and drug-induced extrapyramidal reactions with an extended-release formulation.[5] Both products can command prices materially above generic immediate-release amantadine when payers cover the products and prescribers view the release profile as clinically useful.

Declining influenza demand

The Centers for Disease Control and Prevention has stated that adamantanes should not be used for circulating influenza A viruses because of high resistance levels.[3] This removes a major historical demand driver. Influenza-related sales now have little effect on the commercial trajectory of the amantadine market in the United States.

What is driving the financial trajectory of amantadine products?

The financial trajectory is bifurcated. Legacy amantadine is a mature, low-growth generic market. Extended-release products carry the remaining branded revenue potential.

Revenue drivers for generic amantadine

Generic revenue depends on prescription volume and manufacturer participation rather than brand loyalty. Key drivers include:

• Parkinson's disease prevalence and treatment patterns.
• Use in drug-induced extrapyramidal symptoms.
• Availability of alternative medicines.
• Generic reimbursement rates.
• Product shortages and manufacturing continuity.
• Institutional and pharmacy purchasing contracts.

Generic amantadine has limited ability to expand through price increases without supply disruption or reduced competition.

Revenue drivers for branded extended-release products

Branded extended-release products depend on:

• Diagnosis and treatment of levodopa-induced dyskinesia.
• Specialist prescribing by neurologists and movement-disorder clinics.
• Payer authorization requirements.
• Patient copay support.
• Clinical differentiation from immediate-release amantadine.
• Patent durability.
• Generic or authorized-generic entry.
• Competition from other Parkinson's therapies.

The addressable population is smaller than the broad Parkinson's market, but specialty positioning can support higher revenue per treated patient. The tradeoff is higher commercial spending and greater reimbursement friction.

How strong is the Symmetrel patent estate?

The legacy Symmetrel patent estate is weak as a current commercial asset because the drug is old, the core molecule is generic, and immediate-release competition is established.

Patent strength by product category

Product	Patent strength	Risk profile
Symmetrel immediate-release	Low	No meaningful exclusivity protection
Generic immediate-release amantadine	Not applicable as a franchise	Price and supply risk
Gocovri extended-release	Moderate to strong at the product level, subject to patent validity and litigation	Formulation and method-of-use challenges
Osmolex ER	Moderate at the product level	Extended-release and labeling-related challenges

A formulation patent can protect release characteristics without protecting the active ingredient itself. Method-of-use claims can protect treatment of dyskinesia or other defined patient populations, but their value depends on claim scope, written description, obviousness, infringement, and the ability to enforce the claims against a generic applicant.

Which companies compete with Symmetrel and amantadine?

Symmetrel no longer competes as a major branded product. Competition occurs across therapeutic alternatives and product formats.

Generic manufacturers

Immediate-release amantadine may be supplied by multiple generic manufacturers, depending on market conditions and current FDA approvals. Generic competition generally includes capsule, tablet, and oral-solution products.

Branded amantadine competitors

The principal branded competitors within the amantadine category are:

• Gocovri, marketed by Supernus Pharmaceuticals after its acquisition of Adamas Pharmaceuticals.
• Osmolex ER, developed by Osmotica Pharmaceutical and associated commercial partners.

Therapeutic competitors in Parkinson's disease

Amantadine products compete with:

• Levodopa/carbidopa.
• Dopamine agonists.
• Monoamine oxidase-B inhibitors.
• Catechol-O-methyltransferase inhibitors.
• Deep-brain stimulation for eligible patients.
• Other approaches to motor fluctuations and dyskinesia.

These products do not all compete at the same treatment stage. Gocovri has a more focused position in levodopa-induced dyskinesia, while immediate-release amantadine can be used more broadly but with less commercial differentiation.

What generic entry risks exist for Gocovri and Osmolex ER?

Generic entry risk is higher for extended-release products than for Symmetrel because value depends on formulation and approved use rather than the active ingredient alone.

Gocovri generic risk

A generic applicant could challenge patents covering:

• Extended-release pharmacokinetics.
• Capsule composition.
• Dosing regimen.
• Treatment of levodopa-induced dyskinesia.
• Labeling or use restrictions.

A Paragraph IV certification would notify the branded patent holder that the applicant believes listed patents are invalid, unenforceable, or not infringed. The patent holder could then file litigation, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory conditions and court developments.[7]

Osmolex ER generic risk

Osmolex ER faces comparable risks involving:

• Controlled-release delivery.
• Product composition.
• Dosage strength.
• Use in Parkinson's disease.
• Use in drug-induced extrapyramidal reactions.

The commercial effect of generic entry would depend on whether the applicant can launch an equivalent release profile, secure broad payer substitution, and avoid remaining valid method-of-use claims.

What litigation and settlement issues affect amantadine products?

The key litigation issue is not the old Symmetrel brand. It is the patent enforcement strategy surrounding branded extended-release amantadine.

Potential litigation outcomes include:

Outcome	Effect on market
Patent owner wins	Delays generic entry until patent expiry
Generic invalidates key formulation claims	Accelerates price erosion
Settlement with a delayed launch date	Creates a defined entry window
At-risk launch	Can produce damages exposure and rapid market disruption
Narrow carve-out label	May permit partial generic entry while limiting patented use

Publicly reported litigation and settlement terms must be evaluated product by product. A settlement date does not necessarily equal the earliest legally permitted launch date because regulatory approval, court orders, pediatric exclusivity, reissued patents, and additional listed patents can alter the result.

Does Symmetrel have biosimilar risk?

No. Symmetrel contains a synthetic small molecule, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. The relevant pathway is the abbreviated new drug application route for generic amantadine, with additional product-specific patent issues for extended-release formulations.[7]

How does Symmetrel compare with Gocovri and Osmolex ER?

Attribute	Symmetrel or generic immediate-release amantadine	Gocovri	Osmolex ER
Active ingredient	Amantadine hydrochloride	Amantadine hydrochloride	Amantadine hydrochloride
Release profile	Immediate release	Extended release	Extended release
Main use	Parkinsonism and drug-induced extrapyramidal reactions	Levodopa-induced dyskinesia	Parkinson's disease and drug-induced extrapyramidal reactions
Brand differentiation	Minimal	Clinical and formulation positioning	Formulation and dosing positioning
Pricing power	Low	Higher, subject to payer access	Higher than immediate-release generics
Patent relevance	Low	Material	Material
Generic substitution pressure	Already present	Future or ongoing product-specific risk	Future or ongoing product-specific risk
Revenue outlook	Mature and limited	Specialty-product dependent	Specialty-product dependent

What is the commercial outlook for Symmetrel?

The legacy Symmetrel franchise has no credible path to material growth. Its market position is defined by generic substitution, low pricing, and declining relevance in influenza.

The broader amantadine market has a stable low-value base in immediate-release products and a smaller branded opportunity in extended-release formulations. Revenue growth depends on whether branded products maintain reimbursement and patent protection in Parkinson's disease, particularly dyskinesia.

Base-case market trajectory

• Immediate-release amantadine: flat to declining revenue, with periodic supply-driven volatility.
• Symmetrel brand: negligible or discontinued U.S. revenue contribution.
• Gocovri and Osmolex ER: specialty revenue potential, but exposed to payer restrictions and patent challenges.
• Influenza use: structurally weak in the United States because of resistance.
• Manufacturing economics: favorable for established producers but vulnerable to low-margin supplier exits.
• Investor relevance: concentrated in branded extended-release products and their patent litigation, not in legacy Symmetrel.

Generic launch scenarios

A generic extended-release launch would likely produce:

1. Rapid price reductions if multiple applicants enter.
2. Increased payer preference for generic substitution.
3. Declining branded prescriptions and net price.
4. Greater pressure on patient-support programs.
5. Potential conversion of some patients to low-cost immediate-release amantadine.

The severity of erosion would depend on the number of entrants, regulatory substitutability, patent settlement terms, and whether the generic label includes the branded product's principal indication.

Key Takeaways

• Symmetrel is the historical brand for amantadine hydrochloride.
• Its original immediate-release market has been genericized for decades.
• The influenza indication has little current commercial value because adamantane resistance is widespread.
• There is no biosimilar issue because amantadine is a synthetic small molecule.
• The meaningful patent and revenue analysis concerns extended-release products, especially Gocovri and Osmolex ER.
• Generic immediate-release amantadine has low pricing power and limited growth prospects.
• Branded extended-release amantadine can generate specialty revenue but remains exposed to payer restrictions, patent challenges, and generic entry.
• Symmetrel itself has negligible strategic value as a protected brand franchise.

FAQs

Is Symmetrel still sold in the United States?

Symmetrel has largely been replaced by generic amantadine. Current availability depends on manufacturer and dosage form, but the historical brand is not the central commercial product.

Is amantadine still effective against influenza?

Routine use against seasonal influenza A is not recommended because circulating viruses have high resistance to adamantanes.[3]

What is the difference between Symmetrel and Gocovri?

Both contain amantadine hydrochloride, but Symmetrel is associated with immediate-release amantadine, while Gocovri is an extended-release product approved for levodopa-induced dyskinesia in Parkinson's disease.[1,4]

Can a generic manufacturer copy Gocovri immediately?

No. A generic applicant must obtain FDA approval and address applicable listed patents, regulatory requirements, and any Paragraph IV litigation. The timing of entry depends on the patent and regulatory record.[7]

Is amantadine a high-growth pharmaceutical market?

No. Immediate-release amantadine is a mature generic market. Growth and commercial value are concentrated in differentiated extended-release formulations and targeted Parkinson's indications.

References

1. U.S. Food and Drug Administration. (n.d.). Symmetrel (amantadine hydrochloride) prescribing information. FDA.

2. National Library of Medicine. (n.d.). DailyMed: Amantadine hydrochloride. U.S. National Library of Medicine.

3. Centers for Disease Control and Prevention. (2024). Influenza antiviral medications: Summary for clinicians. CDC.

4. U.S. Food and Drug Administration. (2017). FDA approves new drug to treat dyskinesia in patients with Parkinson's disease. FDA.

5. U.S. Food and Drug Administration. (2018). Osmolex ER approval information. FDA.

6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

7. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Letters and Paragraph IV certifications. FDA.